Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.64 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16803311 | 0.86 | HCRTR2 (0.48) | CYP46A1HCRTR2HCRTR1PKM | |
| SCHEMBL15058495 | 0.84 | ABL1 (0.51) | CYP46A1KDM4EPKML3MBTL1NR4A2 | |
| SCHEMBL9955328 | 0.84 | CYP46A1 (0.63) | CYP46A1HCRTR1KDM4EGLAPKM | |
| SCHEMBL1585974 | 0.83 | HCRTR1 (0.49) | CYP46A1HCRTR2HCRTR1PKML3MBTL1 | |
| SCHEMBL15058274 | 0.83 | HSD17B10 (0.53) | CYP46A1KDM4EPKML3MBTL1TDP1 | |
| SCHEMBL607770 | 0.82 | CSNK2A1 (0.50) | HCRTR2HCRTR1KDM4ETDP1HTT | |
| SCHEMBL16656573 | 0.82 | HCRTR1 (0.49) | CYP46A1HCRTR2HCRTR1 | |
| SCHEMBL29683512 | 0.82 | CSNK2A1 (0.50) | HCRTR2HCRTR1KDM4ETDP1HTT | |
| SCHEMBL19241426 | 0.81 | HCRTR1 (0.48) | CYP46A1HCRTR2HCRTR1PKMMAPT | |
| SCHEMBL1586163 | 0.80 | SLC6A3 (0.54) | KDM4EPKML3MBTL1TDP1MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3676261-B1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LTD (GB) | 2024-12-18 | — | — | EP | disclosed |
| CN-111315734-B | Substituted 2-azabicyclo [3.1.1] heptane and 2-azabicyclo [3.2.1] octane derivatives as orexin receptor antagonists | 克罗诺斯治疗有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | CHRONOS THERAPEUTICS LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | CHRONOS THERAPEUTICS LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | CHRONOS THERAPEUTICS LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| US-20220331299-A1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LIMITED (GB) | 2022-10-20 | — | — | US | disclosed |
| EP-3336088-B1 | CRYSTAL FORM OF OREXIN RECEPTOR ANTAGONIST COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECH CO LTD (CN) | 2021-04-21 | — | — | EP | disclosed |
| US-10912775-B2 | Crystal form of orexin receptor antagonist compound, and preparation method and application thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2021-02-09 | — | — | US | disclosed |
| US-10874674-B2 | Crystal form of orexin receptor antagonist compound, and preparation method and application thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2020-12-29 | — | — | US | disclosed |
| US-20200261453-A1 | CRYSTAL FORM OF OREXIN RECEPTOR ANTAGONIST COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2020-08-20 | — | — | US | disclosed |
| US-20110165632-A1 | Process for the Preparation of an Orexin Receptor Antagonist | MERCK SHARP & DOHME LLC | 2011-07-07 | — | — | US | disclosed |
| EP-2297135-A1 | PROCESS FOR THE PREPARATION OF AN OREXIN RECEPTOR ANTAGONIST | Merck Sharp & Dohme Corp. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20100168134-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-07-01 | — | — | US | disclosed |
| US-20100168134-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-07-01 | — | — | US | disclosed |
| US-20100168134-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-07-01 | — | — | US | disclosed |
| EP-2152690-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2009143033-A1 | PROCESS FOR THE PREPARATION OF AN OREXIN RECEPTOR ANTAGONIST | MERCK & CO., INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009143033-A1 | PROCESS FOR THE PREPARATION OF AN OREXIN RECEPTOR ANTAGONIST | MERCK & CO., INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2008147518-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008147518-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165632-A1 | Process for the Preparation of an Orexin Receptor Antagonist | HCRTR2, HCRTR1, OXTR | CYP46A1 1582/4885HCRTR2 1/4885HCRTR1 2/4885 |
| US-10912775-B2 | Crystal form of orexin receptor antagonist compound, and preparation method and application thereof | HCRTR2, HCRTR1, NPY5R | CYP46A1 505/4885HCRTR2 1/4885HCRTR1 2/4885 |
| US-20220331299-A1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | CYP46A1 709/4885HCRTR2 1/4885HCRTR1 2/4885 |
| US-20100168134-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | CYP46A1 1304/4885HCRTR2 1/4885HCRTR1 2/4885 |
| US-20200261453-A1 | CRYSTAL FORM OF OREXIN RECEPTOR ANTAGONIST COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF | HCRTR2, HCRTR1, NPY5R | CYP46A1 509/4885HCRTR2 1/4885HCRTR1 2/4885 |
| US-10874674-B2 | Crystal form of orexin receptor antagonist compound, and preparation method and application thereof | HCRTR2, HCRTR1, NPY5R | CYP46A1 509/4885HCRTR2 1/4885HCRTR1 2/4885 |
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | HCRTR2, HCRTR1, NPY1R | CYP46A1 709/4885HCRTR2 1/4885HCRTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.